Online Comments to the Pharmaceutical Benefits Advisory Committee (PBAC)

You are welcome to provide comments from a personal or group perspective for consideration by the PBAC when the submission is considered.

Page last updated: 26 May 2015

IMPORTANT: The PBAC operates to a fixed timetable and information received late cannot be considered.

*NOTE: that the closing date for consumer comments is 24 January 2018 for the following submissions:

  • MENINGOGOCCAL POLYSACCHARIDE SEROGROUPS A, C, W-135 AND Y CONJUGATE VACCINE (Nimenrix® /Pfizer Australia Pty Ltd) for the active immunisation of infants for meningococcal disease.
  • TRIVALENT INFLUENZA VACCINE (Fluzone® High-Dose/Sanofi-aventis Australia Pty Ltd) for the prevention of seasonal influenza in patients aged 65 years and over.
  • TRIVALENT INFLUENZA VACCINE (Fluad® /Sequiris Australia Pty Ltd) for the prevention of seasonal influenza in patients aged 65 years and over.

Before completing this form please read the general information sheet.

Comments to the Pharmaceutical Benefits Advisory Committee (PBAC)

Psoriatic arthritis (PsA)
Psoriatic arthritis (PsA)
Maple Syrup Urine Disease (MSUD)
Tyrosinaemia (TYR)
Homocystinuria (HCU)
Parkinson disease
Moderate to severe plaque psoriasis
Urea cycle disorders (UCD)
Hypophosphatasia (HPP)
Uncontrolled severe eosinophilic asthma
Chronic migraine
Clear cell variant renal cell carcinoma (RCC)
Chronic stable plaque type psoriasis vulgaris
Recurrent or metastatic squamous cell carcinoma of the head and neck
Relapsing-remitting multiple sclerosis (RRMS)
Macular oedema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
Atypical haemolytic uraemic syndrome (aHUS) in end stage renal disease (ESRD)
Type 2 diabetes mellitus (T2DM)
Type 2 diabetes mellitus (T2DM)
Rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis, ankylosing spondylitis, juvenile idiopathic arthritis (JIA), paediatric plaque psoriasis
Familial hypercholesterolaemia (FH) with symptomatic atherosclerotic cardiovascular disease (ASCVD)
Chemotherapy-induced neutropenia; Mobilisation of peripheral blood progenitor cells; Assisting bone marrow transplantation; Assisting autologous peripheral blood progenitor cell transplantation; Severe congenital neutropenia; Severe chronic neutropenia; Chronic cyclical neutropenia
Assisted Reproductive Technology (ART); Anovulatory infertility; Infertility due to hypogonadotrophic hypogonadism
Chronic Hepatitis C virus infection
Severe chronic plaque psoriasis
Severe disabling pain
Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL)/relapsed or refractory mantle cell lymphoma (MCL)
Diabetes mellitus
Type 2 diabetes mellitus (T2DM)
Type 2 diabetes mellitus (T2DM)
Metastatic pancreatic cancer
Multiple myeloma
Advanced renal cell carcinoma
Type 2 diabetes mellitus (T2DM)
Meningococcal disease (infants)
Meningococcal disease (adolescents)
Severe eosinophilic asthma
Nicotine dependence
Nicotine dependence
Squamous cell carcinoma for the head and neck (SCCHN)
Treatment of infantile-onset (Type I) spinal muscular atrophy (SMA)
CD20 positive follicular lymphoma
High-grade serous ovarian, fallopian tube and primary peritoneal cancer
Severe chronic spontaneous urticaria
Hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced or metastatic breast cancer
First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC)
Severe dry eye syndrome
Idiopathic pulmonary fibrosis
Prevention of pneumococcal disease
Cow's milk protein enteropathy and intolerance to soy protein; Proven combined immunoglobulin E (IgE) mediated allergy to cows' milk protein and soy protein; Biliary atresia; Chronic liver failure with fat malabsorption; Chylous ascites; Cystic fibrosis; Enterokinase deficiency; Proven fat malabsorption; Severe diarrhoea of greater than 2 weeks duration; Severe intestinal malabsorption including short bowel syndrome
Advanced gastric or gastro-oesophageal junction adenocarcinomas
Visual impairment due choroidal neovascularisation (CNV)
Stable angina pectoris
Hepatocellular carcinoma (HCC)
Hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced or metastatic breast cancer
CD20 positive follicular B-cell non-Hodgkin's lymphoma; Severe active granulomatosis with polyangiitis (Wegeners granulomatosis); CD20 positive non-Hodgkin's lymphoma; Low-grade B-cell non-Hodgkin's lymphoma; Chronic lymphocytic leukaemia; Severe active rheumatoid arthritis
Hyperphenylalaninemia (HPA)
Urea cycle disorder (UCD)
Chronic hepatitis C virus (HCV) infection
Severe myoclonic epilepsy in infancy (SMEI)
Human immunodeficiency virus (HIV) infection
Severe asthma
Autosomal dominant polycystic kidney disease (ADPKD)
Acute and chronic pain
Metastatic colorectal cancer
Proven inborn errors of protein metabolism
Prevention of seasonal influenza
Prevention of seasonal influenza

Below is a section to provide your contact details. These details are not made public or shared with the Committee. Your confidentiality and privacy are protected by the Departmental Officers collating the material. We ask for these individual details only to ensure submissions are recorded accurately and can be confirmed, if required.

Declaration of Interest Statement: The purpose of this declaration is to discover any financial, professional or personal interest on the part of a person, or on the part of their immediate family, who is providing consumer input to the Pharmaceutical Benefits Advisory Committee (PBAC).

For example, a patient has an interest in a particular medicine, because they are currently using it, and wish to see it listed on the PBS.

A doctor may be providing comments, and has also been involved in clinical trials investigating this medicine.

A family member may want to provide comments on a particular medicine that another relative is using, and separately may also have shares in the company which manufactures a number of pharmaceutical drugs, including this specific item.

Such interests may affect or have the appearance of affecting a person’s view on the merits of a drug, vaccine or medicinal preparation being considered by the PBAC.  The existence of such interests may be a ‘conflict of interest’.

A conflict of interest is declared so that information provided can be assessed fairly and in a transparent manner.  The declarations are confidential to the Committee, and do not prevent anyone from still providing their comments as they to submit.

A conflict of interest can be declared, but does not mean a person should not still provide their comments.

A financial interest may include, but is not limited to, any of the following involvement with companies or other organisations engaged in the development, manufacture, marketing or distribution of vaccines, drugs and medicinal preparations:

  1. current shareholdings;
  2. board memberships or other offices;
  3. paid employment or contracting work;
  4. grants for overseas travel or conference expenses;
  5. significant hospitality.

A professional interest may include, but is not limited to, involvement in any of the following:

  1. development, manufacture or marketing and distribution of vaccines, drugs and medicinal preparations;
  2. making a public statement about that company or a drug or other product of that company.

A personal interest may include, but is not limited to, any of the following:

  1. where  you are writing to support a drug being listed on the PBS, because you have a condition or illness for which that drug may be being considered by the PBAC;
  2. an immediate family is aware that a relative close to them suffers from a condition for which a drug before the PBAC may be being considered by the PBAC;
  3. where you or your immediate family has strong personal or religious beliefs about a drug or treatment under consideration by the PBAC.

  • How does this condition/disease affect quality of life?
  • What would you most like to see from this treatment? Improved side effects? Slowing disease progression? More mobility? Other benefits?
  • If you have used or prescribed this new medicine, what was your experience of the beneficial effects?
  • If you have used or prescribed this new medicine, what side effects or toxicities did you experience or observe?
  • If you haven't used the new medicine yet, what are your expectations of it?
  • If you use other currently available therapies or medicines you use to manage your condition (or for prescribers, for your patient’s condition), what are the benefits and/ or the challenges?
  • Where did you obtain the information that helped form your views on this treatment?
    • I have been a patient on this medicine;
    • Your doctor;
    • Other patients stories/experiences
    • Professional colleagues;
    • Support networks;
    • Own research;
    • Other patient resources;
    • Direct experience as a health professional or carer;
    • Other – please provide details.

Thank you for your time and participation in this process.

*Agree to terms and conditions

The Department may use this information to verify that any individual or organisation is bonafide or if any comments need clarification. Personal information collected by the Department will not be provided to any other organisation or used for any other purpose. The personal information of individuals will be de-identified before comments are considered by the PBAC.

Disclaimer: The comments contained in this document are not those of the Department, the sponsor company or the PBAC and are the responsibility of the individual or group, making the submission.

If you have problems submitting this form please contact the PBAC Secretariat ( If you are submitting a hardcopy of this form please mail to: PBAC Secretariat – MDP 952, Department of Health and Ageing, GPO Box 9848, Canberra ACT 2601 or fax to (02) 6289 4175.